MCID: ACT010
MIFTS: 55

Acth-Secreting Pituitary Adenoma

Categories: Rare diseases, Cancer diseases, Endocrine diseases, Genetic diseases, Reproductive diseases

Aliases & Classifications for Acth-Secreting Pituitary Adenoma

MalaCards integrated aliases for Acth-Secreting Pituitary Adenoma:

Name: Acth-Secreting Pituitary Adenoma 12 53 44 15 73
Cushing Disease 53 25
Pituitary-Dependant Hypercortisolism Disorder 25
Pituitary-Dependent Cushing's Disease 73
Pituitary Corticotroph Micro-Adenoma 53
Pituitary Dependent Cushing Syndrome 53
Pituitary-Dependent Cushing Syndrome 53
Pituitary-Dependant Cushing Syndrome 25
Pituitary-Dependant Hypercortisolism 25
Pituitary-Dependent Cushings Disease 55
Adenoma, Pituitary, Acth-Secreting 40
Pituitary Adenoma, Acth-Secreting 13
Acth-Producing Pituitary Adenoma 12
Pituitary Acth-Secreting Adenoma 13
Corticotroph Pituitary Adenoma 53
Pituitary Acth Hypersecretion 25
Adrenal Gland Hyperfunction 73
Pituitary Cushing Syndrome 25
Corticotroph Adenoma 12
Cushing's Disease 53
Hypercortisolism 25
Cushing Syndrome 73
Corticotropinoma 12

Classifications:



Summaries for Acth-Secreting Pituitary Adenoma

Genetics Home Reference : 25 Cushing disease is caused by elevated levels of a hormone called cortisol, which leads to a wide variety of signs and symptoms. This condition usually occurs in adults between the ages of 20 and 50; however, children may also be affected. The first sign of this condition is usually weight gain around the trunk and in the face. Affected individuals may get stretch marks (striae) on their thighs and abdomen and bruise easily. Individuals with Cushing disease can develop a hump on their upper back caused by abnormal deposits of fat. People with this condition can have muscle weakness, severe tiredness, and progressively thin and brittle bones that are prone to fracture (osteoporosis). They also have a weakened immune system and are at an increased risk of infections. Cushing disease can cause mood disorders such as anxiety, irritability, and depression. This condition can also affect a person's concentration and memory. People with Cushing disease have an increased chance of developing high blood pressure (hypertension) and diabetes. Women with Cushing disease may experience irregular menstruation and have excessive hair growth (hirsutism) on their face, abdomen, and legs. Men with Cushing disease may have erectile dysfunction. Children with Cushing disease typically experience slow growth.

MalaCards based summary : Acth-Secreting Pituitary Adenoma, also known as cushing disease, is related to adrenal gland hyperfunction and pituitary-dependent cushing's disease, and has symptoms including cushingoid facies An important gene associated with Acth-Secreting Pituitary Adenoma is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Myometrial Relaxation and Contraction Pathways and Prolactin Signaling Pathway. The drugs Somatostatin and Zinc have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and adrenal gland, and related phenotypes are menorrhagia and round face

Disease Ontology : 12 A functioning pituitary adenoma that characterized by excess cortisol a primary cause of Cushing's syndrome.

NIH Rare Diseases : 53 ACTH-secreting pituitary adenoma is a condition characterized by elevated levels of a hormone called cortisol secreted by a tumor in the pituitary gland. It is part of a group of diseases that cause Cushing’s syndrome, characterized by signs and symptoms that may include weight gain around the trunk and in the face, stretch marks, easy bruising, a hump on the upper back, muscle weakness, tiredness, thin bones that are prone to fracture (osteoporosis), mood disorders and memory problems, as well as an increased risk of infections, high blood pressure and diabetes. Women may have irregular menses and a lot of hair in the body (hirsutism). It  occurs when a benign pituitary tumor (adenoma) or pituitary hyperplasia causes the adrenal glands to produce large amounts of cortisol.  Some cases are caused by somatic mutations in the AIP and the GNAS genes. Rarely, an ACTH-secreting pituitary adenoma can be inherited, either as an isolated condition or as part of a genetic syndrome (such as multiple endocrine neoplasia type 1 (MEN1) and familial isolated pituitary adenoma), but most cases are sporadic. Treatment generally involves surgery to remove the tumor and medications to decrease cortisol levels.

Wikipedia : 76 Cushing\'s syndrome is a collection of signs and symptoms due to prolonged exposure to cortisol. Signs... more...

Related Diseases for Acth-Secreting Pituitary Adenoma

Diseases in the Acth-Secreting Pituitary Adenoma family:

Pituitary Adenoma 4, Acth-Secreting

Diseases related to Acth-Secreting Pituitary Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Related Disease Score Top Affiliating Genes
1 adrenal gland hyperfunction 31.6 CRH NR3C1 POMC PRL
2 pituitary-dependent cushing's disease 31.3 CRH POMC PRL
3 conn's syndrome 29.8 CRH NR3C1 POMC
4 pituitary adenoma 4, acth-secreting 11.3
5 malignant acth producing neoplasm of pituitary gland 10.9
6 pituitary adenoma 10.7
7 adenoma 10.7
8 hyperaldosteronism, familial, type i 10.4 NR3C1 POMC
9 apparent mineralocorticoid excess 10.4 NR3C1 POMC
10 corticosteroid-binding globulin deficiency 10.4 NR3C1 POMC
11 allergic urticaria 10.4 CRH NR3C1
12 primary pigmented nodular adrenocortical disease 10.3 NR3C1 POMC
13 lymphocytic hypophysitis 10.3 POMC TBX19
14 hypoadrenalism 10.3 CRH POMC
15 fasting hypoglycemia 10.3 CRH POMC
16 adrenal cortical hypofunction 10.3 CRH POMC
17 withdrawal disorder 10.2 CRH POMC
18 ectopic cushing syndrome 10.2 CRH POMC
19 persistent fetal circulation syndrome 10.2 CRH POMC
20 hypokalemia 10.2 NR3C1 POMC
21 endogenous depression 10.2 CRH POMC
22 pituitary infarct 10.2 POMC PRL
23 hypoadrenocorticism, familial 10.2 CRH POMC
24 adenohypophysitis 10.2 POMC PRL
25 chiasmal syndrome 10.2 POMC PRL
26 pituitary apoplexy 10.2 POMC PRL
27 sella turcica neoplasm 10.2 POMC PRL
28 tuberculum sellae meningioma 10.2 POMC PRL
29 empty sella syndrome 10.2 POMC PRL
30 hyperpituitarism 10.2 POMC PRL
31 hypothyroidism, congenital, nongoitrous, 4 10.2 POMC PRL
32 central nervous system organ benign neoplasm 10.2 POMC PRL
33 functioning pituitary adenoma 10.1 POMC PRL
34 diabetes insipidus, neurohypophyseal 10.1 POMC PRL
35 adrenal adenoma 10.1 CRH POMC
36 sex differentiation disease 10.1 POMC PRL
37 gonadal disease 10.1 CRH POMC
38 melancholia 10.1 CRH PRL
39 chromophobe adenoma 10.1 POMC PRL
40 pituitary tumors 10.1 POMC PRL
41 pituitary hormone deficiency, combined, 2 10.1 POMC PRL
42 gynecomastia 10.0 POMC PRL
43 thyroid gland disease 10.0 POMC PRL
44 organ system benign neoplasm 10.0 POMC PRL
45 adrenal carcinoma 10.0 CRH POMC
46 postpartum depression 10.0 CRH PRL
47 osteoporosis 10.0
48 leukemia 10.0
49 cryptococcal meningitis 10.0
50 teratoma 10.0

Graphical network of the top 20 diseases related to Acth-Secreting Pituitary Adenoma:



Diseases related to Acth-Secreting Pituitary Adenoma

Symptoms & Phenotypes for Acth-Secreting Pituitary Adenoma

Human phenotypes related to Acth-Secreting Pituitary Adenoma:

32 (show all 41)
# Description HPO Frequency HPO Source Accession
1 menorrhagia 32 frequent (33%) HP:0000132
2 round face 32 hallmark (90%) HP:0000311
3 visual impairment 32 occasional (7.5%) HP:0000505
4 cataract 32 occasional (7.5%) HP:0000518
5 visual loss 32 occasional (7.5%) HP:0000572
6 psychosis 32 occasional (7.5%) HP:0000709
7 depressivity 32 frequent (33%) HP:0000716
8 anxiety 32 frequent (33%) HP:0000739
9 nephrolithiasis 32 frequent (33%) HP:0000787
10 infertility 32 frequent (33%) HP:0000789
11 diabetes mellitus 32 frequent (33%) HP:0000819
12 hypertension 32 frequent (33%) HP:0000822
13 osteoporosis 32 frequent (33%) HP:0000939
14 thin skin 32 hallmark (90%) HP:0000963
15 bruising susceptibility 32 frequent (33%) HP:0000978
16 acne 32 frequent (33%) HP:0001061
17 lethargy 32 occasional (7.5%) HP:0001254
18 failure to thrive 32 hallmark (90%) HP:0001508
19 recurrent skin infections 32 occasional (7.5%) HP:0001581
20 cardiomyopathy 32 occasional (7.5%) HP:0001638
21 truncal obesity 32 hallmark (90%) HP:0001956
22 abdominal pain 32 occasional (7.5%) HP:0002027
23 generalized hirsutism 32 frequent (33%) HP:0002230
24 headache 32 occasional (7.5%) HP:0002315
25 sleep disturbance 32 occasional (7.5%) HP:0002360
26 immunodeficiency 32 frequent (33%) HP:0002721
27 recurrent fractures 32 frequent (33%) HP:0002757
28 pituitary adenoma 32 hallmark (90%) HP:0002893
29 hypokalemia 32 frequent (33%) HP:0002900
30 myopathy 32 occasional (7.5%) HP:0003198
31 venous thrombosis 32 occasional (7.5%) HP:0004936
32 bipolar affective disorder 32 occasional (7.5%) HP:0007302
33 generalized hyperpigmentation 32 occasional (7.5%) HP:0007440
34 premature ovarian insufficiency 32 occasional (7.5%) HP:0008209
35 adrenal hyperplasia 32 hallmark (90%) HP:0008221
36 lipodystrophy 32 hallmark (90%) HP:0009125
37 aseptic necrosis 32 occasional (7.5%) HP:0010885
38 onychomycosis 32 occasional (7.5%) HP:0012203
39 fatigue 32 frequent (33%) HP:0012378
40 telangiectasia of the skin 32 occasional (7.5%) HP:0100585
41 metrorrhagia 32 frequent (33%) HP:0100608

UMLS symptoms related to Acth-Secreting Pituitary Adenoma:


cushingoid facies

MGI Mouse Phenotypes related to Acth-Secreting Pituitary Adenoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.73 CRH NR3C1 POMC PRKCD PRL TBX19
2 integument MP:0010771 9.55 TBX19 CRH NR3C1 POMC PRL
3 liver/biliary system MP:0005370 9.35 CRH NR3C1 POMC PRKCD PRL
4 nervous system MP:0003631 9.1 TBX19 CRH NR3C1 POMC PRKCD PRL

Drugs & Therapeutics for Acth-Secreting Pituitary Adenoma

Drugs for Acth-Secreting Pituitary Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2 38916-34-6, 51110-01-1 53481605
2
Zinc Approved, Investigational Phase 4 7440-66-6 23994
3
Metformin Approved Phase 4 657-24-9 14219 4091
4
Liraglutide Approved Phase 4 204656-20-2 44147092
5
Lactitol Investigational Phase 4 585-86-4 3871
6 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
7 Hormones Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
9 insulin Phase 4
10 Insulin, Globin Zinc Phase 4
11
protease inhibitors Phase 4
12 Sitagliptin Phosphate Phase 4
13 HIV Protease Inhibitors Phase 4
14 Dipeptidyl-Peptidase IV Inhibitors Phase 4
15 Hypoglycemic Agents Phase 4,Phase 2
16 Incretins Phase 4
17
Epinephrine Approved, Vet_approved Phase 3,Phase 2,Not Applicable 51-43-4 5816
18
Racepinephrine Approved Phase 3,Phase 2,Not Applicable 329-65-7 838
19
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
20
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
21
Cabergoline Approved Phase 3,Phase 2 81409-90-7 54746
22
Mifepristone Approved, Investigational Phase 3,Phase 2,Not Applicable 84371-65-3 55245
23
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
24 Orange Approved, Nutraceutical Phase 3
25 Epinephryl borate Phase 3,Phase 2,Not Applicable
26 beta-endorphin Phase 3,Phase 2
27 Dopamine agonists Phase 3,Phase 2
28 Adrenocorticotropic Hormone Phase 3,Phase 2,Early Phase 1
29 Contraceptive Agents Phase 3,Phase 2,Not Applicable
30 Contraceptives, Oral Phase 3,Phase 2,Not Applicable
31 Contraceptives, Postcoital Phase 3,Phase 2,Not Applicable
32 Cortisol succinate Phase 3,Phase 2
33 Neurotransmitter Agents Phase 3,Phase 2
34 Dopamine Agents Phase 3,Phase 2
35 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2
36 Hydrocortisone acetate Phase 3,Phase 2
37 Pharmaceutical Solutions Phase 3
38 Antiparkinson Agents Phase 3,Phase 2
39 Luteolytic Agents Phase 3,Phase 2,Not Applicable
40 Melanocyte-Stimulating Hormones Phase 3,Phase 2
41 Gastrointestinal Agents Phase 3,Phase 2
42 Edotreotide Phase 3
43 Radiopharmaceuticals Phase 3
44 Antineoplastic Agents, Hormonal Phase 3,Phase 2
45
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
46
Bexarotene Approved, Investigational Phase 1, Phase 2 153559-49-0 82146
47
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
48
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
49
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
50
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
2 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
3 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
4 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
5 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
6 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
7 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
8 Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
9 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00936741 Phase 3 mifepristone
10 A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome Completed NCT00569582 Phase 3 mifepristone
11 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease Recruiting NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
12 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
13 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Active, not recruiting NCT02180217 Phase 3 LCI699
14 Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
15 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
16 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
17 Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment Unknown status NCT02713776 Phase 2 Pasireotide;Placebo
18 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
19 A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
20 Treatment of Cushing's Disease With R-roscovitine Recruiting NCT02160730 Phase 2 R-roscovitine
21 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
22 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Recruiting NCT02468193 Phase 2 Osilodrostat
23 Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Recruiting NCT02749227 Phase 2 Pasireotide LAR
24 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2 Lapatinib
25 Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Active, not recruiting NCT01915303 Phase 2 Pasireotide with or without cabergoline
26 Safety and Efficacy of LCI699 in Cushing's Disease Patients. Active, not recruiting NCT01331239 Phase 2 LCI699
27 Study to Evaluate CORT125134 in Patients With Cushing's Syndrome Active, not recruiting NCT02804750 Phase 2 CORT125134
28 Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) Terminated NCT00612066 Phase 2 rosiglitazone maleate
29 Rosiglitazone in Treating Patients With Pituitary Tumors Terminated NCT00616642 Phase 2 rosiglitazone maleate
30 Pasireotide Therapy in Patients With Nelson's Syndrome Terminated NCT01617733 Phase 2 Pasireotide
31 Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Terminated NCT00422201 Phase 2 Mifepristone
32 Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma Terminated NCT00813592 Phase 2 SOM230B
33 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
34 SOM230 Ectopic ACTH-producing Tumors Withdrawn NCT02780882 Phase 2 Pasireotide
35 Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease Unknown status NCT02603653 Not Applicable
36 Study of Depression, Peptides, and Steroids in Cushing's Syndrome Unknown status NCT00004334
37 Mutations of Glucocorticoid Receptor in Bilateral Adrenal Hyperplasia Unknown status NCT02810496 Not Applicable
38 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332 Not Applicable
39 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335
40 The Factors Associated With the Recurrence in Patients With Cushing Disease Completed NCT02233335
41 Cognition, Steroids, and Imaging in Cushings Disease Completed NCT00081341
42 Effects of Hormone Stimulation on Brain Scans for Cushing s Disease Completed NCT01459237 Early Phase 1 Acthrel
43 Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome Completed NCT00001453
44 Examination of Brain Serotonin Receptors in Patients With Mood Disorders Completed NCT00026832
45 Obesity as a Risk Factor for Musculoskeletal Diseases in the U.S. Air Force: Associations and Implications for Force Readiness Completed NCT01613001
46 Cushing's Disease Complications Recruiting NCT02568982
47 Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease Recruiting NCT02310269 SOM230
48 Collecting Information About Treatment Results for Patients With Cushing's Syndrome Recruiting NCT03364803
49 Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B. Recruiting NCT02651844 Not Applicable Mifepristone
50 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601

Search NIH Clinical Center for Acth-Secreting Pituitary Adenoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: acth-secreting pituitary adenoma

Genetic Tests for Acth-Secreting Pituitary Adenoma

Anatomical Context for Acth-Secreting Pituitary Adenoma

MalaCards organs/tissues related to Acth-Secreting Pituitary Adenoma:

41
Pituitary, Bone, Adrenal Gland, Skin, Brain, Breast, Liver

Publications for Acth-Secreting Pituitary Adenoma

Articles related to Acth-Secreting Pituitary Adenoma:

(show all 31)
# Title Authors Year
1
Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection. ( 29143885 )
2018
2
Protein expression of somatostatin receptor 2, somatostatin receptor 5 and dopamine D2 receptor in normal pituitary gland and ACTH-secreting pituitary adenoma in dogs. ( 29864631 )
2018
3
Cryptococcal meningitis after transnasal transsphenoidal pituitary microsurgery of ACTH-secreting pituitary adenoma: A case report. ( 28700464 )
2017
4
Correction: Lycopene and Beta-Carotene Induce Growth Inhibition and Proapoptotic Effects on ACTH-Secreting Pituitary Adenoma Cells. ( 26848958 )
2016
5
Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma. ( 28005257 )
2016
6
Phenotype-Genotype Association Analysis of ACTH-Secreting Pituitary Adenoma and Its Molecular Link to Patient Osteoporosis. ( 27690016 )
2016
7
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells. ( 26522132 )
2016
8
Ectopic ACTH-secreting pituitary adenoma of the sphenoid sinus: case report of endoscopic endonasal resection and systematic review of the literature. ( 25639312 )
2015
9
Bone morphogenetic protein 4 and bone morphogenetic protein receptor expression in the pituitary gland of adult dogs in healthy condition and with ACTH-secreting pituitary adenoma. ( 26542941 )
2015
10
Nasally located ectopic ACTH-secreting pituitary adenoma (EAPA) causing Nelson's syndrome: diagnostic challenges. ( 24065616 )
2013
11
Lycopene and beta-carotene induce growth inhibition and proapoptotic effects on ACTH-secreting pituitary adenoma cells. ( 23667519 )
2013
12
miR-26a plays an important role in cell cycle regulation in ACTH-secreting pituitary adenomas by modulating protein kinase CI'. ( 23525216 )
2013
13
Downregulation of Insulin-like growth factor binding protein 6 is associated with ACTH-secreting pituitary adenoma growth. ( 24379119 )
2013
14
Lack of mutations in the gene coding for the hGR (NR3C1) in a pediatric patient with ACTH-secreting pituitary adenoma, absence of stigmata of Cushing's syndrome and unusual histologic features. ( 22570980 )
2012
15
Liver X receptor-I+/I^ expression ratio is increased in ACTH-secreting pituitary adenomas. ( 21356276 )
2011
16
ICA Occlusion by an ACTH-secreting pituitary adenoma post-TSS and irradiation. ( 22399870 )
2011
17
Visual vignette. Ectopic ACTH-secreting pituitary adenoma. ( 21803709 )
2011
18
Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli. ( 20719856 )
2010
19
Upregulation of CDKN2A and suppression of cyclin D1 gene expressions in ACTH-secreting pituitary adenomas. ( 20616110 )
2010
20
An ACTH-secreting pituitary adenoma within the sphenoid sinus. ( 20424367 )
2010
21
Ghrelin stimulates adrenocorticotrophic hormone (ACTH) secretion by human ACTH-secreting pituitary adenomas in vitro. ( 17280594 )
2007
22
A patient with recurrent hypercortisolism after removal of an ACTH-secreting pituitary adenoma due to an adrenal macronodule. ( 17185905 )
2006
23
ACTH-secreting pituitary adenoma within an ovarian teratoma. ( 16137552 )
2005
24
Mutation analysis of leukemia inhibitory factor-receptor (LIF-R) in ACTH-secreting pituitary adenomas. ( 15372367 )
2004
25
Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. ( 12379847 )
2002
26
Decreased expression of corticotropin-releasing factor-binding protein mRNA in ACTH-secreting pituitary adenomas. ( 10768834 )
2000
27
Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. ( 7508871 )
1994
28
Vasopressin enhances a calcium current in human ACTH-secreting pituitary adenoma cells. ( 2844618 )
1988
29
Failure of valproic acid to inhibit the growth of an ACTH-secreting pituitary adenoma. ( 6326445 )
1984
30
ACTH secreting pituitary adenoma in an infant of 18 months. Immunohistochemical, electron-microscopic, and in-vitro studies. ( 6278457 )
1981
31
Increase of beta-endorphin in cerebrospinal fluid after removal of ACTH-secreting pituitary adenoma. ( 6272176 )
1981

Variations for Acth-Secreting Pituitary Adenoma

Cosmic variations for Acth-Secreting Pituitary Adenoma:

9
(show all 33)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM4997287 USP8 pituitary,NS,adenoma,ACTH c.2152T>C p.S718P 15:50490443-50490443 52
2 COSM416905 USP8 pituitary,NS,adenoma,ACTH c.2159C>A p.P720Q 15:50490450-50490450 52
3 COSM5967228 USP8 pituitary,NS,adenoma,ACTH c.2155T>C p.S719P 15:50490446-50490446 52
4 COSM1749198 USP8 pituitary,NS,adenoma,ACTH c.2159C>G p.P720R 15:50490450-50490450 52
5 COSM5967229 USP8 pituitary,NS,adenoma,ACTH c.2153C>T p.S718F 15:50490444-50490444 52
6 COSM5991542 STAG2 pituitary,NS,adenoma,ACTH c.1363G>C p.G455R 23:124057924-124057924 52
7 COSM28544 PIK3CA pituitary,NS,adenoma,ACTH c.3026G>A p.G1009E 3:179234183-179234183 52
8 COSM303944 PIK3CA pituitary,NS,adenoma,ACTH c.2984C>A p.A995D 3:179234141-179234141 52
9 COSM22589 MEN1 pituitary,NS,adenoma,ACTH c.1230C>A p.F410L 11:64805154-64805154 52
10 COSM482 HRAS pituitary,NS,adenoma,ACTH c.34G>C p.G12R 11:534289-534289 52
11 COSM27887 GNAS pituitary,NS,adenoma,ACTH c.601C>T p.R201C 20:58909365-58909365 52
12 COSM27896 GNAS pituitary,NS,adenoma,ACTH c.680A>G p.Q227R 20:58909541-58909541 52
13 COSM5991541 BCOR pituitary,NS,adenoma,ACTH c.283G>A p.G95R 23:40075063-40075063 52
14 COSM10654 TP53 skin,face,other,hyperplasia c.637C>T p.R213* 17:7674894-7674894 5
15 COSM10995 TP53 skin,face,other,hyperplasia c.580C>T p.L194F 17:7674951-7674951 5
16 COSM43939 TP53 skin,face,other,hyperplasia c.632C>T p.T211I 17:7674899-7674899 5
17 COSM45444 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.587G>T p.R196L 17:7674944-7674944 4
18 COSM43555 TP53 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.736A>G p.M246V 17:7674227-7674227 4
19 COSM225014 RB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.1960G>A p.V654M 13:48456349-48456349 4
20 COSM4167506 PRKACA adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.617T>G p.L206R 19:14097604-14097604 4
21 COSM27899 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.601C>A p.R201S 20:58909365-58909365 4
22 COSM27895 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.602G>A p.R201H 20:58909366-58909366 4
23 COSM4962873 GNAS adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.679C>G p.Q227E 20:58909540-58909540 4
24 COSM5663 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.133T>C p.S45P 3:41224645-41224645 4
25 COSM5689 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.134C>G p.S45C 3:41224646-41224646 4
26 COSM5678 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.107A>C p.H36P 3:41224619-41224619 4
27 COSM5667 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.134C>T p.S45F 3:41224646-41224646 4
28 COSM5686 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.100G>A p.G34R 3:41224612-41224612 4
29 COSM5679 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.110C>G p.S37C 3:41224622-41224622 4
30 COSM17661 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.130C>G p.P44A 3:41224642-41224642 4
31 COSM5988492 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.101G>C p.G34A 3:41224613-41224613 4
32 COSM5681 CTNNB1 adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.95A>G p.D32G 3:41224607-41224607 4
33 COSM476 BRAF adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producing c.1799T>A p.V600E 7:140753336-140753336 4

Expression for Acth-Secreting Pituitary Adenoma

Search GEO for disease gene expression data for Acth-Secreting Pituitary Adenoma.

Pathways for Acth-Secreting Pituitary Adenoma

GO Terms for Acth-Secreting Pituitary Adenoma

Biological processes related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.35 CRH IGFBP6 NR3C1 POMC PRKCD
2 cellular response to dexamethasone stimulus GO:0071549 8.62 CRH NR3C1

Molecular functions related to Acth-Secreting Pituitary Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.33 CRH IGFBP6 POMC
2 neuropeptide hormone activity GO:0005184 8.96 CRH POMC
3 hormone activity GO:0005179 8.8 CRH POMC PRL

Sources for Acth-Secreting Pituitary Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....